Immunology and Bi...
Follow
Find
7.8K views | +5 today
 
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

Optimal trough Remicade and antibody levels for IBD maintenance - IBDwatch

Optimal trough Remicade and antibody levels for IBD maintenance - IBDwatch | Immunology and Biotherapies | Scoop.it
Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Clinical improvement in psoriasis with specific targeting of interleukin-23

Abstract

 

Psoriasis is a chronic inflammatory skin disorder that affects approximately 2–3% of the population worldwide and has severe effects on patients’ physical and psychological well-being1, 2, 3. The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. Evidence suggests that specific inhibition of IL-23 would result in improvement in psoriasis. Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL-23p19 subunit, in a three-part, randomized, placebo-controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoriasis to provide clinical proof that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects. A 75% reduction in the psoriasis area and severity index (PASI) score (PASI75) was achieved by all subjects in parts 1 and 3 (pooled) in the 3 and 10 mg kg−1 groups by day 196. In part 2, 10 out of 15 subjects in the 3 mg kg−1 group and 13 out of 14 subjects in the 10 mg kg−1 group achieved a PASI75 by day 112. Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis patients as demonstrated by improvements in PASI scores and histological samples.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 14, 3:07 AM

NATURE | LETTER

Clinical improvement in psoriasis with specific targeting of interleukin-23Tamara Kopp,Elisabeth Riedl,Christine Bangert,Edward P. Bowman,Elli Greisenegger,Ann Horowitz,Harald Kittler,Wendy M. Blumenschein,Terrill K. McClanahan,Thomas Marbury,Claus Zachariae,Danlin Xu,Xiaoli Shirley Hou,Anish Mehta,Anthe S. Zandvliet,Diana Montgomery,Frank van Aarle& Sauzanne KhaliliehAffiliationsContributionsCorresponding authorNature 521, 222–226 (14 May 2015) doi:10.1038/nature14175Received 23 December 2013 Accepted 23 December 2014 Published online 09 March 2015Corrected online 13 May 2015
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Frontiers | Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies | NK Cell Biology

Natural killer (NK) cells belong to innate immunity and exhibit cytolytic activity against infectious pathogens and tumor cells. NK-cell function is finely tuned by receptors that transduce inhibit...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Melanoma BRAF Inhibitors Review
Scoop.it!

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

Findings

The anti-PD-1 and anti-PD-L1 agents have been reported to have impressive antitumor effects in several malignancies, including melanoma. The greatest clinical activity in unselected patients has been seen in melanoma. Tumor expression of PD-L1 is a suggestive, but inadequate, biomarker predictive of response to immune-checkpoint blockade. However, tumors expressing little or no PD-L1 are less likely to respond to PD-1 pathway blockade. Combination checkpoint blockade with PD-1 plus cytotoxic T-lymphocyte antigen (CTLA)-4 blockade appears to improve response rates in patients who are less likely to respond to single-checkpoint blockade. Toxicity with PD-1 blocking agents is less than the toxicity with previous immunotherapies (eg, interleukin 2, CTLA-4 blockade). Certain adverse events can be severe and potentially life threatening, but most can be prevented or reversed with close monitoring and appropriate management.

Implications

This family of immune-checkpoint inhibitors benefits not only patients with metastatic melanoma but also those with historically less responsive tumor types. Although a subset of patients responds to single-agent blockade, the initial trial of checkpoint-inhibitor combinations has reported a potential to improve response rates. Combination therapies appear to be a means of increasing response rates, albeit with increased immune-related adverse events. As these treatments become available to patients, education regarding the recognition and management of immune-related effects of immune-checkpoint blockade will be essential for maximizing clinical benefit.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 15, 4:02 AM

doi:10.1016/j.clinthera.2015.02.018

 

Clinical Therapeutics

Volume 37, Issue 4, 1 April 2015, Pages 764–782

Review Article The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaKathleen M. Mahoney, MD, PhD1, 2, , , Gordon J. Freeman, PhD2, David F. McDermott, MD1

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Scientist Solutions - Monoclonal Antibody Epitope Mapping

Large Searchable List of Antibody protocols online
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Finding should enhance treatments that stop immune system attacks

Finding should enhance treatments that stop immune system attacks | Immunology and Biotherapies | Scoop.it
An important discovery has been made about an immune cell that is already being used in immunotherapy to treat diseases such as type I diabetes. The work details how regulatory T cells can cure inflammatory diseases, researchers say.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Advances in monoclonal antibody therapy for multiple myeloma

Advances in monoclonal antibody therapy for multiple myeloma | Immunology and Biotherapies | Scoop.it
At the Myeloma 2015 meeting, Dr Joseph Mikhael (Mayo Clinic, Scottsdale, AZ) discusses the development of monoclonal antibodies (mAbs), including anti-CD38 mAbs, SAR650984 and daratumumab, and anti-SLAMF7 mAb, elotuzumab, for the treatment of...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

BRIEF-Theradiag launches Lisa Tracker in Canada - Reuters

May 11 (Reuters) - Theradiag SA :* Theradiag launches Lisa Tracker in Canada* Exclusive partnership agreement with Somagen DiagnosticsInc* Positive recommendation by Canadian Health Authorities onbiotherapy...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level? - Duquesnoy - 2015 - American Journal of Transplantation -...

Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level? - Duquesnoy - 2015 - American Journal of Transplantation -... | Immunology and Biotherapies | Scoop.it
Should #HLA Mismatch Acceptability for Sensitized Candidates Be Determined at the High-Res Rather Than Antigen Level? http://t.co/mkZcz582EI
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors : Nature Medicine : Nature Publishing Group

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors : Nature Medicine : Nature Publishing Group | Immunology and Biotherapies | Scoop.it
Crystal Mackall and colleagues report that antigen-independent signaling of chimeric antigen receptors (CARs) causes T cell exhaustion and reduced therapeutic efficacy of CAR T cells that can be overcome by incorporating the 4-1BB costimulatory...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1

Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1 | Immunology and Biotherapies | Scoop.it
by Vanessa Kruse, Carina Hamann, Sebastian Monecke, Lukas Cyganek, Leslie Elsner, Daniela Hübscher, Lutz Walter, Katrin Streckfuss-Bömeke, Kaomei Guan, Ralf Dressel Human induced pluripotent stem cells (hiPSCs) could be used to generate autologous...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Introduction to Regulatory Science at the FDA

Dr. Anne Plant, NIST speaks at the 2015 workshop "Characterizing Cell Populations through Dynamic Quantitative Imaging and Molecular Analysis: Challenges ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Regenerative Medicine highlights the immunological challenges that lie ahead ... - Medical Xpress

Regenerative Medicine highlights the immunological challenges that lie ahead ... - Medical Xpress | Immunology and Biotherapies | Scoop.it
The journal Regenerative Medicine has published a special focus issue on methods to avoid immune rejection in regenerative medicine.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Overview | Cancer Immunology & Immunotherapy | Research Solutions | PerkinElmer

Overview | Cancer Immunology & Immunotherapy | Research Solutions | PerkinElmer | Immunology and Biotherapies | Scoop.it
Our Cancer Immunology & Immunotherapy Research Solutions include advanced staining methods, multispectral imaging systems, image analysis services, and contract services.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Safety and activity of the anti-CD79B antibody–...

Safety and activity of the anti-CD79B antibody–... | Immunology and Biotherapies | Scoop.it
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study - The Lanc...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. - PubMed - NCBI

Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Cytotherapy. 2015 May 9. pii: S1465-3249(15)00855-5. doi: 10.1016/j.jcyt.2015.04.002. [Epub ahead of print]
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Bertilimumab - Immune Pharmaceuticals

Bertilimumab is a fully human, IgG4-type monoclonal antibody (mAb) that blocks the activity of a protein called eotaxin-1 that plays an important role in inflammation in multiple clinical indications.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 5, 4:31 AM

Immune Pharmaceuticals Inc., a clinical stage bio-pharmaceutical company with a monoclonal antibody, bertilimumab, for the treatment of auto-immune diseases, and STC Biologics, a biotechnology development company led by alumni of Genentech, Shire, Novartis and Merrimack Pharmaceuticals, announced today that they are entering into a strategic partnership to accelerate the development of NanomAbs, a new generation of Antibody Nanoparticle Conjugates allowing the targeted delivery of chemo-therapeutics.



Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers

First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers | Immunology and Biotherapies | Scoop.it
(2014). First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. mAbs: Vol. 6, No. 6, pp. 1649-1656. doi: 10.4161/19420862.2014.976431
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Melanoma BRAF Inhibitors Review
Scoop.it!

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Abstract

Enhancing immune responses with immune-modulatory monoclonal antibodies directed to inhibitory immune receptors is a promising modality in cancer therapy. Clinical efficacy has been demonstrated with antibodies blocking inhibitory immune checkpoints such as cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) or PD-1/PD-L1. Treatment with ipilimumab, a fully human CTLA-4–specific mAb, showed durable clinical efficacy in metastatic melanoma; its mechanism of action is, however, only partially understood. This is a study of 29 patients with advanced cutaneous melanoma treated with ipilimumab. We analyzed peripheral blood mononuclear cells (PBMCs) and matched melanoma metastases from 15 patients responding and 14 not responding to ipilimumab by multicolor flow cytometry, antibody-dependent cell-mediated cytotoxicity (ADCC) assay, and immunohistochemistry. PBMCs and matched tumor biopsies were collected 24 h before (i.e., baseline) and up to 4 wk after ipilimumab. Our findings show, to our knowledge for the first time, that ipilimumab can engage ex vivo FcγRIIIA (CD16)-expressing, nonclassical monocytes resulting in ADCC-mediated lysis of regulatory T cells (Tregs). In contrast, classical CD14++CD16−monocytes are unable to do so. Moreover, we show that patients responding to ipilimumab display significantly higher baseline peripheral frequencies of nonclassical monocytes compared with nonresponder patients. In the tumor microenvironment, responders have higher CD68+/CD163+ macrophage ratios at baseline and show decreased Treg infiltration after treatment. Together, our results suggest that anti–CTLA-4 therapy may target Tregs in vivo. Larger translational studies are, however, warranted to substantiate this mechanism of action of ipilimumab in patients.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 10, 1:55 PM

PNAS

Emanuela Romano, doi: 10.1073/pnas.1417320112

 

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patientsEmanuela Romanoa,b,c,1, Monika Kusio-Kobialkab, Periklis G. Foukasc,d, Petra Baumgaertnerc,Christiane Meyerc, Pierluigi Ballabenie, Olivier Michielina,c, Benjamin Weidef, Pedro Romeroc, andDaniel E. Speiserc

Author Affiliations

Edited by Ira Mellman, Genentech, Inc., South San Francisco, CA, and approved March 30, 2015 (received for review September 9, 2014)

Krishan Maggon 's curator insight, May 12, 3:05 AM

PNAS

Emanuela Romano, doi: 10.1073/pnas.1417320112

 

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patientsEmanuela Romanoa,b,c,1, Monika Kusio-Kobialkab, Periklis G. Foukasc,d, Petra Baumgaertnerc,Christiane Meyerc, Pierluigi Ballabenie, Olivier Michielina,c, Benjamin Weidef, Pedro Romeroc, andDaniel E. Speiserc

Author Affiliations

Edited by Ira Mellman, Genentech, Inc., South San Francisco, CA, and approved March 30, 2015 (received for review September 9, 2014)

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Removing Aggregates in Monoclonal Antibody Purification

Removing Aggregates in Monoclonal Antibody Purification | Immunology and Biotherapies | Scoop.it
Several chromatographic resins are available for downstream purification.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Promise of Cancer Immunotherapy | Biotech Strategy Blog

Promise of Cancer Immunotherapy highlighted at Immunology 2015 annual meeting of American Association of Immunologists
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the ... - Science Magazine

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2: Cancer Cell

Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2: Cancer Cell | Immunology and Biotherapies | Scoop.it
Highlights

 

•Serum-persistent IL-2 and anti-tumor IgG induces strong control of tumor growth•Immune response includes a cytokine storm with high levels of MIP-2, IFNγ, and IL-6•Neutrophils drive efficacy, and infiltration is mediated by NK cells and macrophages•Adoptive transfer of CD8+ T cells, Fc/IL-2, and antibody confers long-term efficacy

 

Summary

Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody and an untargeted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive isogenic tumor models via a concerted innate and adaptive response involving neutrophils, NK cells, macrophages, and CD8+ T cells. This combination therapy induces an intratumoral “cytokine storm” and extensive lymphocyte infiltration. Adoptive transfer of anti-tumor T cells together with this combination therapy leads to robust cures of established tumors and development of immunological memory.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 9, 11:01 AM

Cancer Cell

Volume 27, Issue 4, p489–501, 13 April 2015ArticleSwitch to Standard ViewSynergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2Eric F. Zhu12, Shuning A. Gai12, Cary F. Opel12, Byron H. Kwan, Rishi Surana, Martin C. Mihm, Monique J. Kauke,Kelly D. Moynihan, Alessandro Angelini, Robert T. Williams, Matthias T. Stephan, Jacob S. Kim, Michael B. Yaffe, Darrell J. Irvine,Louis M. Weiner, Glenn Dranoff, K. Dane Wittrup12Co-first author DOI: http://dx.doi.org/10.1016/j.ccell.2015.03.004 |  ;
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Role of CD154 in cancer pathogenesis and immunotherapy - Cancer Treatment Reviews

Role of CD154 in cancer pathogenesis and immunotherapy - Cancer Treatment Reviews | Immunology and Biotherapies | Scoop.it
Highlights

 

CD154 is a co-stimulatory molecule known for its role in inflammatory and autoimmune diseases.

CD154 and its receptor, CD40 are expressed in many types of tumors.

The CD154/CD40 interaction is capable of inducing the proliferation and rescue from apoptosis of tumor cells.

CD154 activates anti-tumoral immunity, and by engaging CD40 may induce apoptosis of tumor cells.

The role of CD154 in cancer immunotherapy was demonstrated in animal models and clinically assessed in patients.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 10, 2:00 AM

doi:10.1016/j.ctrv.2015.03.007

 

Cancer Treatment Reviews

Volume 41, Issue 5, May 2015, Pages 431–440

Laboratory-Clinic Interface Role of CD154 in cancer pathogenesis and immunotherapyGhada S. Hassan, John Stagg, Walid Mourad, 
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Frontiers | Improving the safety of cell therapy with the TK-suicide gene | Experimental Pharmacology and Drug Discovery

While opening new frontiers for the cure of malignant and non-malignant diseases, the increasing use of cell therapy poses also several new challenges related to the safety of a living drug.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Mersana's cancer-fighting antibody-drug conjugate shows promise in animal studies

Mersana's cancer-fighting antibody-drug conjugate shows promise in animal studies | Immunology and Biotherapies | Scoop.it
Fierce 15 member Mersana Therapeutics, a developer of customizable next-generation antibody-drug conjugates, announced that its lead anticancer candidate showed promise in preclinical studies.

Via Krishan Maggon
more...
No comment yet.